Evidence map›Paper›PMID 39964679›Full record

ArticleJAMA network open2025

Tobacco and E-Product Use by US Adults With Disabilities.

Michael J Parks, Daniela Marshall, Heather L Kimmel, John H Kingsbury, Colm D Everard, Eiman Aboaziza, Carlos Blanco, Wilson M Compton

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Tobacco Product Use and Type by Military Veteran Status: Findings from the National Health Interview Survey, 2021-2023.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael J ParksNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Daniela MarshallNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Heather L KimmelNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
John H KingsburyNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Colm D EverardNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Eiman AboazizaNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Carlos BlancoNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Wilson M ComptonNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Research on cumulative disabilities and tobacco use in the current tobacco landscape is lacking. Objective: To examine prevalence of tobacco use across cumulative disabilities within and across years among US adults. Design, Setting, and Participants: Representative cross-sectional surveys of the US adult (aged ≥18 years) civilian, noninstitutionalized population from the Population Assessment of Tobacco and Health (PATH) Study were compared across 2013 to 2014 (wave 1), 2016 to 2018 (wave 4), and 2022 to 2023 (wave 7). Age-adjusted estimates and change scores were compared using design-based significance tests. Data were analyzed from November 2023 and April 2024. Main Outcomes and Measures: Past 30-day use of tobacco (cigarette, electronic nicotine [e-product], traditional cigar, filtered cigar, cigarillo, pipe, hookah, and smokeless products); disability types (mobility, self-care, independent living, cognitive, hearing, and vision) summed to generate a 4-level cumulative disability measure (0, 1, 2, or ≥3). Results: In 2013 to 2014, among 32 314 participants at wave 1, 3110 participants were 65 years or older (18.2%), 15 993 (51.9%) were female, 5536 (15.2%) were Hispanic, 4496 (11.2%) were non-Hispanic Black, 19 295 (66.0%) were non-Hispanic White, and 2428 (7.5%) were another non-Hispanic race. A total of 32 314 adults were included in 2013 to 2014, 33 638 in 2016 to 2018, and 30 681 in 2022 to 2023. In 2013 to 2014, any tobacco use prevalence for those with no disabilities was 25.4% (95% CI, 24.7% to 26.1%), while prevalence was 40.2% (95% CI, 38.6% to 41.8%), 48.9% (95% CI, 45.4% to 52.5%), and 51.8% (95% CI, 48.6% to 55.0%) for those with 1, 2, and 3 or more disabilities, respectively. Any tobacco, cigarette, e-product, cigarillo, filtered cigar, and pipe use were consistently higher among those with multiple disabilities compared with those with 0 or 1 disability. Prevalence was highest among those with 3 or more disabilities for all products. Tobacco use declined over time, except e-product use increased. However, not all declines in prevalence between 2013 to 2014 and 2022 to 2023 were significant among those with 3 or more disabilities. The declines for those who used any tobacco (-4.6%; 95% CI, -8.7% to -0.6%) and cigarettes (-8.9%; 95% CI, -12.7% to -5.1%) were small, and increases in e-product use were large (4.6%; 95% CI, 1.0% to 8.3%) for those with 3 or more disabilities compared with other groups. Conclusions and Relevance: In this survey study, disparities in tobacco use existed across cumulative disabilities. Despite declines in tobacco use over time, differences in use across cumulative disabilities persisted or worsened, especially among those with 3 or more disabilities. Targeted prevention, screening, and cessation efforts inclusive of multiple products are needed.

Indexed as

Electronic Nicotine Delivery SystemsPersons with DisabilitiesTobacco ProductsTobacco UseVapingAdolescentAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrevalenceUnited StatesYoung Adult

Identifiers

PMID39964679
PMCPMC11836758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.